Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RFA with Bevacizumab and second-line chemotherapy for unresectable CRLM
NCT03686254Phase 3Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jul 2018
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in colorectal liver metastases (CRLM), sponsored by Nanfang Hospital, Southern Medical University. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
colorectal liver metastases (CRLM)
Beyond the preview
Go deeper on NCT03686254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03686254.